Aerin Medical Reports Two Year Results of VivAer (AERWAY) Study for Nasal Airway Obstruction
Shots:
- The 2yr. follow-up data from the (AERWAY) trial evaluating the VivAer system, a non-invasive technology that uses patented, temperature-controlled radiofrequency energy in patients with sev. or extreme NAO due to nasal valve collapse
- The results showed a significant & sustained improvement in symptom burden in all subpopulations incl. NVC patients with untreated septal deviations & either static or dynamic NVC, 90.1% were responders & improvements in NOSE scale scores were maintained from the time of treatment. The results were presented at Laryngoscope Investigative Otolaryngology
- Usage of oral medications, nasal sprays & breathing strips decreased at 2yr. VivAer was well-tolerated with no serious AEs related to the procedure and/or device
Ref: Businesswire | Image: Aerin Medical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
